About Stem Cells Bank
Stem Cells Bank Biotechnological Company engaged in development of autovaccines for treating oncological diseases and tuberculosis, produced on the basis of autologous dendritic cells (cells extracted from the organism of the very patient to be given the vaccine). In the framework of thus project it is planned to develop and launch a vaccine for treating oncological diseases and tuberculosis, produced on the basis of cells extracted from the organism of the very patient to be given the vaccine.
Latest Stem Cells Bank News
Jun 16, 2017
Bookmark Romanian MedLife, the private medical services provider, has acquired an additional 40 percent stake from Stem Cells Bank from Timisoara, one of the most modern stem cells banks from South-Eastern Europe. „In 2015, we announced the entry on a new business segment, once with the start of the acquisition of the main stake from Stem Cells Bank and the decision of acquiring another stake of 40 percent is a natural step in the development of our business. Once with the integration of this service, we could offer complete solutions to mother and child, currently having over 24,000 births in our three maternities,” said Mihai Marcu, president and general director of MedLife. In addition, MedLife takes an additional 3 percent stake from Genesys Medical Clinic group from Arad, one of the biggest medical services operators from Western Romania, taking its ownership to 58 percent. MedLife Genesys Arad includes a hospital, maternity, ambulatory and a laboratory. Stem Cells Bank was launched on 2010 at Timisoara and it’s based on Biosafe Sepax 2 technology, the only private stem cells bank from Balkanic area that uses this technology, through which the manufacturing and isolation of stem cells is automatized. Since 2010 until now, MedLife closed 15 acquisitions.
Stem Cells Bank Frequently Asked Questions (FAQ)
What is Stem Cells Bank's latest funding round?
Stem Cells Bank's latest funding round is Seed.
How much did Stem Cells Bank raise?
Stem Cells Bank raised a total of $500K.
Who are the investors of Stem Cells Bank?
Investors of Stem Cells Bank include Tomsk Venture Investment Centre.
Who are Stem Cells Bank's competitors?
Competitors of Stem Cells Bank include Noveome Biotherapeutics, La Jolla Pharmaceutical Company, Longevica, Endocyte, Tau Therapeutics and 7 more.
Compare Stem Cells Bank to Competitors
NKT Thereapeutics develops therapeutics based on a subset of immune cells called natural killer T cells.
Decimmune Therapeutics focuses on the development of therapeutic antibodies in the biotechnology sector. The company's main product, a novel monoclonal antibody, is designed to prevent tissue damage and preserve organ function in various vascular inflammatory diseases. The primary market for Decimmune Therapeutics includes the healthcare sector, specifically targeting the treatment of vascular inflammatory conditions. It was founded in 2001 and is based in Cambridge, Massachusetts.
REGiMMUNE is a biotechnology company focused on the development of novel medicines for immune disorders. The company's main offerings include treatments designed to modulate the immune system and harness a patient's own immune response for inducing tolerance and achieving anti-tumor effects. These therapies are aimed at a range of immune-related conditions. It was founded in 2006 and is based in Tokyo, Japan.
Dare Bioscience operates a healthcare company. Its commitment is to develop and commercialize innovative products in women's reproductive health. Dare Bioscience was formerly known as Tempo Pharmaceuticals. The company was founded in 2005 and is based in San Diego, California.
LeukoSight is a biopharmaceutical company focused on developing anti-inflammatory therapeutics for autoimmune and inflammatory diseases. The company's main innovation involves reprogramming white blood cells to secrete immunoregulatory molecules, aiming to create treatments that are potentially less toxic and more effective than current options. LeukoSight's primary market includes sectors dealing with multiple sclerosis and other autoimmune/inflammatory conditions. It is based in Columbia, Maryland.
Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.